icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Boston MA
November 2019
Back grey_arrow_rt.gif
Changes in Insulin Resistance Out to 3 Years After
Successful Interferon-Free Treatment of Chronic HCV Infection

  AASLD November 8-12, 2019, Boston, Massachusetts
Mário Jorge Silva1, Filipe Calinas1, Diogo Bento2, Eric Crown3, Wenjing Lu3, Mariem Charafeddine3*, Armen Asatryan3, Franco Felizarta4, Douglas Dieterich5, Fred Poordad6, Curtis Cooper7, Dominique Larrey8, Daniel E Cohen3, Patrice Cacoub91Gastroenterology Department, Hospital de Santo António dos Capuchos, Centro Hospitalar e Universitário de Lisboa Central, Lisbon, Portugal; 2AbbVie Lda., Amadora, Portugal; 3AbbVie Inc., North Chicago, Illinois, United States; 4Private Practice, Bakersfield, California, United States; 5Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, United States; 6The Texas Liver Institute/University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States; 7Department of Medicine, Division of Infectious Diseases, University of Ottawa, Ottawa, Canada; 8Service des maladies de l'appareil digestif, Hôpital Saint Eloi, IBR-Inserm, Montpellier, France; 9Sorbonne Universite, UPMC University of Paris and Inflammation-Immunopathology-Biotherapy Department and INSERM, UMR_S 959 and CNRS FRE3632 and AP-HP, Groupe Hospitalier Pitie-Salpêtrière, Department of Internal Medicine and Clinical Immunology, Paris, France*Current employee of Vaccitech Limited, Oxford, United Kingdom.Current employee of AveXis Inc., a Novartis company, Bannockburn, Illinois, United States